Jun. 16 at 8:38 PM
$IGC expands CALMA Phase II Alzheimer’s Trial to Include Renowned Butler Hospital's Memory and Aging Program.
We’re proud to share that IGC Pharma has expanded its Phase 2 clinical trial, CALMA, to include the prestigious Butler Hospital's Memory and Aging Program, affiliated with the Warren Alpert Medical School of Brown University in Providence, Rhode Island.
The CALMA trial is evaluating IGC-AD1, our investigational therapy for agitation in Alzheimer’s disease, a condition that affects the majority of people living with Alzheimer’s and significantly impacts caregivers.
Butler Hospital's Memory and Aging Program is nationally recognized for its leadership in Alzheimer’s research. The program is committed to advancing care and improving outcomes for patients and families.
This collaboration marks an important milestone as we continue moving closer to delivering a potential new treatment for those affected by agitation in Alzheimer’s.
#igcpharma #alzheimersresearch #igcad1 #neuroscience
